Wyeth trims Canadian OTC brands
This article was originally published in The Tan Sheet
Executive Summary
The pharmaceutical and nutritional products firm becomes a leaner acquisition for Pfizer by divesting Anacin pain relief and other OTC brands in Canada to Paladin Labs. Montreal-based Paladin June 29 said it agreed to acquire multiple OTC products including Anacin (acetylsalicylic acid) and Anbesol (benzocaine) topical pain reliever. The firms did not disclose the terms of the deal, but market analysts said Paladin likely paid a discounted price because Wyeth was interested in divesting the brands in advance of being acquired by Pfizer for $68 billion (1"The Tan Sheet" Feb. 2, 2009). Wyeth sold the U.S. Anacin brand to Insight Pharmaceuticals in 2003. According to Paladin, which also markets Rx drugs, in 2008 the Wyeth Canadian OTC brands generated $4 million Canadian ($3.46 million U.S.)
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.